Announced Wed, 15 Jul · 08:34 IST
Zydus says Delhi HC order on cancer drug IkraTM is not material
Regulatory & Legal View source PDF
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.5%1-day move
₹1133.80
prior close
₹1145.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.6-0.8-0.6-0.7+1.5+0.9+1.3+1.1-0.8-2.1————
Up moveDown movePending
AI summary
BSE asked Zydus Lifesciences to clarify a Delhi High Court order that temporarily restricts the company from supplying its cancer drug IkraTM. Zydus responded that this event is not material under SEBI listing rules and its own materiality policy. The company said there was no material movement in its share price on July 14, 2026, and believes the order will not have a material impact on its business or operations.
Likely market impact
Company downplays court order restricting cancer drug supply; maintains no material impact on business or stock trading.